Literature DB >> 7913442

The effect of dexamethasone on time averaged mean velocity in the middle cerebral artery in very low birth weight infants.

A Ohlsson1, J Bottu, J Govan, M L Ryan, T Myhr, K Fong.   

Abstract

The effect of repeated doses of dexamethasone (0.25 mg/kg/dose every 12 h) on time averaged mean velocity in the middle cerebral artery was assessed in ten ventilated very low birth weight infants requiring treatment with dexamethasone for bronchopulmonary dysplasia or airway obstruction. The infants were studied by colour/duplex Doppler technique prior to the administration of the first and the third dose of dexamethasone, and 10, 30, and 120 min after these doses. Dexamethasone treatment was associated with an improvement in infant lung condition, an increase in mean arterial blood pressure and a decrease in heart rate. The time averaged mean velocity was statistically significantly reduced at 120 min after the first dose. This was not associated with a decrease in PCO2. The observed reduction of 18% from baseline in the time averaged mean velocity is unlikely to be of clinical importance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7913442     DOI: 10.1007/bf01956420

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  24 in total

1.  Cerebral blood flow and indomethacin drug levels in subjects with and without central nervous side effects.

Authors:  P Seideman; M von Arbin
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

2.  Cerebral blood flow velocity regulation in preterm infants.

Authors:  M van de Bor; F J Walther
Journal:  Biol Neonate       Date:  1991

Review 3.  The effectiveness and side effects of dexamethasone in preterm infants with bronchopulmonary dysplasia.

Authors:  P C Ng
Journal:  Arch Dis Child       Date:  1993-03       Impact factor: 3.791

4.  Change in blood pressure after treatment of patent ductus arteriosus with indomethacin.

Authors:  N Evans; P Iyer
Journal:  Arch Dis Child       Date:  1993-05       Impact factor: 3.791

5.  Cerebral blood flow velocity changes in preterm infants after a single dose of indomethacin: duration of its effect.

Authors:  F Van Bel; M Van de Bor; T Stijnen; J Baan; J H Ruys
Journal:  Pediatrics       Date:  1989-11       Impact factor: 7.124

6.  Quantitative EEG changes due to cerebral vasoconstriction. Indomethacin versus hyperventilation-induced reduction in cerebral blood flow in normal subjects.

Authors:  V Kraaier; A C Van Huffelen; G H Wieneke; H B Van der Worp; P R Bär
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1992-03

7.  Effect of indomethacin on cerebral blood flow velocities in very low birth weight neonates with a patent ductus arteriosus.

Authors:  A Ohlsson; J Bottu; J Govan; M L Ryan; K Fong; T Myhr
Journal:  Dev Pharmacol Ther       Date:  1993

8.  Effects of indomethacin on cerebral hemodynamics at rest and during endotracheal suctioning in preterm neonates.

Authors:  E Saliba; A Chantepie; E Autret; F Gold; L Pourcelot; J Laugier
Journal:  Acta Paediatr Scand       Date:  1991 Jun-Jul

9.  Regional cerebral blood flow velocity changes after indomethacin infusion in preterm infants.

Authors:  N C Austin; P W Pairaudeau; T K Hames; M A Hall
Journal:  Arch Dis Child       Date:  1992-07       Impact factor: 3.791

10.  Dexamethasone in neonatal chronic lung disease: pulmonary effects and intracranial complications.

Authors:  C M Noble-Jamieson; R Regev; M Silverman
Journal:  Eur J Pediatr       Date:  1989-01       Impact factor: 3.183

View more
  2 in total

1.  Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants.

Authors: 
Journal:  Paediatr Child Health       Date:  2002-01       Impact factor: 2.253

2.  Effects of betamethasone administration to the fetal sheep in late gestation on fetal cerebral blood flow.

Authors:  M Schwab; M Roedel; M A Anwar; T Müller; H Schubert; L F Buchwalder; B Walter; W Nathalielsz
Journal:  J Physiol       Date:  2000-11-01       Impact factor: 5.182

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.